Pfizer is in preliminary talks to acquire drug maker Seagen, the Wall Street Journal reported, citing people familiar with the matter. The report said Seagen has a market value of around $30 billion and is expected to have a premium on that amount, adding that negotiations for a deal are in the preliminary stages.